DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for dysembryoplastic neuroepithelial tumor — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDysembryoplastic neuroepithelial tumor maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dysembryoplastic neuroepithelial tumor is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
isocitrate dehydrogenase (NADP(+)) 1 (IDH1) — IDH1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ictdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6BKX · 1.65 Å · ligand ISOCITRIC ACID (ICT). Experimental structure, not a prediction.
What the evidence adds up to
A 2011 case report describes a 16-year-old female with headache and convulsion for two months; MRI showed a brain tumour later confirmed as dysembryoplastic neuroepithelial tumour by histopathology. A 2021 report describes a 16-year-old girl whose DNET was diagnosed at age 6, treated with gross total resection, and followed by serial imaging. She had been seizure-free but then presented with a focal seizure; MRI revealed recurrence of a peripherally located lesion ten years after the original surgery. No other treatments or drug interventions are mentioned in these abstracts.
The 2004 and 2016 abstracts are learning objectives and a methods statement, respectively, and provide no patient outcome data, survival figures, or response rates. The 2016 abstract notes that DNET is a rare, usually benign paediatric brain tumour presenting generally with seizures, and states the goal was to evaluate the role of surgery for seizure control, but the full text is not provided here.
No drug, chemotherapy, or targeted therapy is discussed in any of these abstracts. The only intervention described is surgery (gross total resection), and the 2021 report documents that recurrence can occur even after complete resection and a decade of seizure freedom. There is no evidence from these abstracts to support any pharmacological treatment for DNET.
What is missing are prospective studies with sufficient sample sizes to determine whether any systemic therapy has a role in DNET, particularly for recurrent or incompletely resected cases. No trial has tested a drug in this population, no molecular stratification has been linked to treatment response, and no funding source has been identified for such work.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pulse · 2011 · 5 citations · open access
Dysembryoplastic neuroepithelial tumour: A case report
AbstractAim and Objective: Dysembryoplastic neuroepithelial tumour is an unusual brain tumour with varied incidence commonly occured in younger age group. We report a 16-year old female diagnosed as a case of dysembryoplastic neuroepithelial tumour. Clinical presentation: A 16 year old female was examined for headache and convulsion for two months. MRI revealed a brain tumour which was later confirmed as dysembyroplastic neuroepithelial tumour by histopathological examination.DOI: http://dx.doi.org/10.3329/pulse.v4i1.6968Pulse Vol.4 January 2010 p.43-44
AbstractLearning Objectives: After reading this article, the participant should be able to: Identify the clinical and radiological findings in patients with dysembryoplastic neuroepithelial tumors. Describe the pathological findings in patients with dysembryoplastic neuroepithelial tumors. Discuss the outcome of patients with dysembryoplastic neuroepithelial tumors.
German Medical Science (German Research Foundation) · 2016 · 0 citations · open access
Dysembryoplastic neuroepithelial tumors in pediatric patients: Long-term follow-up
AbstractObjective: Dysembryoplastic Neuroepithelial Tumor (DNET) is a rare, usually benign pediatric brain tumor that is presenting generally with seizures. The optimal management and long-term outcome is uncertain. The goal of this study was to evaluate the role of surgery for seizure control. Method: We[for full text, please go to the a.m. URL]
BMJ Case Reports · 2021 · 0 citations · open access
Recurrence of unusual dysembryoplastic neuroepithelial tumour with novel molecular features presenting 10 years after gross total resection
AbstractA 16-year-old girl with a prior history of a dysembryoplastic neuroepithelial tumour (DNET) diagnosed at the age of 6 years, treated with a gross total resection and followed by serial imaging, who had been seizure-free, presented with a focal seizure. MRI revealed recurrence of a peripherally
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
